Search

Displaying results 3331 - 3340 of 10000 in total
  1. Drug

    Reviparin

    go.drugbank.com/drugs/DB09259
    Approved

    Reviparin has a molecular weight of 3.9 kDa.[A32021] It was developed by Abbott laboratories and in 2009, reviparin presented an orphan drug designation by the FDA.[L1469] … Reviparin is a low molecular weight heparin which seems to have a better safety profile than unfractionated heparin.

    Products: CLIVARIN 5726 IE A XA/ML, CLIVARODI 17178 A XA/ML
  2. Drug

    Antihemophilic factor, human recombinant

    go.drugbank.com/drugs/DB00025
    ApprovedInvestigational

    Human recombinant antihemophilic factor (AHF) or Factor VIII, 2332 residues, glycosylated, produced by CHO cells

    Categories: Hemophilia A
  3. Drug

    Oxalic Acid

    go.drugbank.com/drugs/DB03902
    Experimental

    A strong dicarboxylic acid occurring in many plants and vegetables. It is produced in the body by metabolism of glyoxylic acid or ascorbic acid. It is not metabolized but excreted in the urine. … It is used as an analytical reagent and general reducing agent. [PubChem]

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    CHGN111

    go.drugbank.com/drugs/DB06376
    Experimental

    Numerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at critical cellular sites, as well as in a decrease of systemic oxidative … CHGN111 is an inhibitor of the mitochondrial enzyme CLK-1 which is a demethoxyubiquinone hydroxylase.

  5. Drug

    Ethylmorphine

    go.drugbank.com/drugs/DB01466
    IllicitInvestigational

    A narcotic analgesic and antitussive. It is metabolized in the liver by ethylmorphine-N-demethylase and used as an indicator of liver function. … It is not marketed in the US but is approved for use in various countries around the world. In the US it is a schedule II drug (single-entity) and schedule III drug (in combination products).

  6. Drug

    INNO-305

    go.drugbank.com/drugs/DB06025
    Investigational

    INNO-305 is an investigational vaccine developed by Innovive Pharmaceuticals for the treatment of patients with acute myeloid leukemia in complete remission. … The vaccine is a polyvalent Wilms tumor gene 1 (WT1) peptide analog vaccine.

  7. Drug

    Chlorotrianisene

    go.drugbank.com/drugs/DB00269
    ApprovedWithdrawn

    A powerful synthetic, non-steroidal estrogen. [PubChem]

    International brands: Tace FN
  8. Drug

    NS-2359

    go.drugbank.com/drugs/DB05805
    Investigational

    This mode of action is expected to produce an optimal reduction in all disease symptoms and the possibility of an earlier onset of action compared to antidepressants already on the market. … NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression.

  9. Drug

    Guselkumab

    go.drugbank.com/drugs/DB11834
    ApprovedInvestigational

    Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. … In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological manifestations of psoriasis.

    Products: TREMFYA SOLUTION FOR INJECTION IN PRE-FILLED PEN 100MG/ML, TREMFYA SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 100MG/1ML
  10. Drug

    Eravacycline

    go.drugbank.com/drugs/DB12329
    ApprovedInvestigational

    It was first approved by the FDA on August 27, 2018 [L4540]. … Eravacycline, known as _Xerava_ by Tetraphase Pharmaceuticals, is a fully synthetic fluorocycline antibiotic of the tetracycline class with activity against clinically significant gram-negative, gram-positive

    Categories: Monoamine Oxidase A Substrates